TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25367544

Group type: EXPERIMENTAL
Intervention: individual‐ESI
Number of subjects: 82

Group type: COMPARATOR
Intervention: group‐ESI
Number of subjects: 82
Study: 22369682

Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitors (80 mg bolus, followed by pantoprazole 8 mg/h infusion, n = 100)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard-dose proton pump inhibitors (pantoprazole 40 mg bolus daily, n = 101)
Number of subjects: 201
Study: 20061123

Group type: EXPERIMENTAL
Intervention: Rufinamide 200mg/day
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Rufinamide 400mg/day
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Rufinamide 800mg/day
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Rufinamide 1600mg/day
Number of subjects: 647

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study: 18947287

Group type: EXPERIMENTAL
Intervention: Quartz‐tungsten‐halogen (QTH) curing unit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Plasma arc curing (PAC) unit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Light-emitting diode (LED) unit
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional halogen light (Control)
Number of subjects: 45
Study: 15795027

Group type: EXPERIMENTAL
Intervention: Cooperative learning and case study (n=31)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Lecture and large group case study (n=46)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Lecture only (n=24)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Lecture and occasional use of non-cooperative learning groups (n=22)
Number of subjects: 123
Study: 12576970

Group type: EXPERIMENTAL
Intervention: Mannitol administration for >72 hrs (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mannitol administration for 24 to 48 hrs (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 30
Study: 11215153

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8660168

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 26
Study: 2002646

Group type: EXPERIMENTAL
Intervention: Cyclosporin A therapy (10 mg/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Blood transfusions (3 to 5 third-party transfusions at two weekly intervals)
Number of subjects: 16
Study: 6408031

Group type: EXPERIMENTAL
Intervention: Individual dietetic counselling
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group dietetic counselling
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group dietetic counselling with behaviour modification
Number of subjects: 36
Study: 30421537

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 8-week treatment
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 12-week treatment
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 16-week treatment
Number of subjects: 693
Study: 29451696

Group type: EXPERIMENTAL
Intervention: Pemetrexed (arm 1)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Pemetrexed and bevacizumab (arm 2)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Pemetrexed, carboplatin, and bevacizumab (arm 3)
Number of subjects: 172
Study: 27629490

Group type: EXPERIMENTAL
Intervention: Retrograde intubation (RI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 100
Study: 24854809

Group type: EXPERIMENTAL
Intervention: Sad mood condition
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Neutral mood condition
Number of subjects: 85
Study: 22669067

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) including hypnosis; 6-session program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conservative standard treatment for TMD
Number of subjects: 72
Study: 20472510

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 18323230

Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuroleptic anaesthesia
Number of subjects: 0
Study: 15966131

Group type: EXPERIMENTAL
Intervention: Combination inhaled corticosteroids and long acting beta agonists (ICS/LABA)
Number of subjects: 0
Study: 12198062

Group type: EXPERIMENTAL
Intervention: ropivacaine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ropivacaine plus clonidine 30 microg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ropivacaine plus clonidine 60 microg
Number of subjects: 77
Study: 10561258

Group type: EXPERIMENTAL
Intervention: Chemoradiation (epirubicin 60 mg/m(2)) followed by adjuvant chemotherapy (epirubicin 90 mg/m(2) at 4-week intervals for five cycles)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard pelvic radiotherapy
Number of subjects: 220
Study: 8607100

Group type: EXPERIMENTAL
Intervention: Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 115
Study: 1309115

Group type: EXPERIMENTAL
Intervention: hMG (FSH:LH = 1:1) administered to 18 patients (group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Highly purified hMG (FSH:LH = 19:1) administered to 19 patients (group B)
Number of subjects: 37
Study: 3918356

Group type: EXPERIMENTAL
Intervention: 2 mg sodium cromoglycate aerosol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mg sodium cromoglycate aerosol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20 mg sodium cromoglycate aerosol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 12 mg nebulised sodium cromoglycate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30516064

Group type: EXPERIMENTAL
Intervention: Consensus on Exercise Reporting Template
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Template for Intervention Description and Replication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus on Therapeutic Exercise Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2016 American College of Sports Medicine guidelines (aerobic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2016 American College of Sports Medicine guidelines (flexibility and resistance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All reporting tools
Number of subjects: 0
Study: 30012190

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) of all brain metastases (up to ten lesions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 56
Study: 26620682

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 76

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 76

Group type: COMPARATOR
Intervention: Topical pharyngeal anaesthesia
Number of subjects: 76
Study: 25027170

Group type: EXPERIMENTAL
Intervention: CHA-CHA (split-course accelerated hyperfractionated irradiation)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional (Conv.) arm
Number of subjects: 101
Study: 22789440

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1g intravenously in a single dose before surgery)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Cefazolin (1g intravenously in a single dose before surgery)
Number of subjects: 320
Study: 20508026

Group type: EXPERIMENTAL
Intervention: AS03(B) adjuvanted split virion vaccine
Number of subjects: 943

Group type: COMPARATOR
Intervention: Non-adjuvanted whole virion vaccine
Number of subjects: 943
Study: 18593681

Group type: EXPERIMENTAL
Intervention: Insulin administered via pen devices (n = 49)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional vials and syringes (n = 45)
Number of subjects: 94
Study: 15973830

Group type: EXPERIMENTAL
Intervention: Ultrasonic periodontal treatment (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No ultrasonic scaling (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Group 3) - adults without PD, Community Periodontal Index of Treatment Needs = 0
Number of subjects: 50
Study: 12048127

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 5 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) 5 mg/day plus vitamin C 500 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 100
Study: 10453490

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH) 0.15 IU/(kg.day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH)
Number of subjects: 18
Study: 8190404

Group type: EXPERIMENTAL
Intervention: Pyloroplasty or pyloromyotomy (group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No drainage procedures (group B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups A and B combined
Number of subjects: 38
Study: 2455109

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg b.i.d. in a slow-release formulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine and Atenolol combination
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31853609

Group type: EXPERIMENTAL
Intervention: Bemiparin 3500 IU q24h starting 6 hours after procedure for at least 10 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Enoxaparin 40 IU q24h starting 6 hours after procedure for at least 10 days
Number of subjects: 78
Study: 29476776

Group type: EXPERIMENTAL
Intervention: Propranolol (nonspecific β1‐, β2‐adrenergic receptor inverse agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catecholamine stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal β2‐AR ubiquitination
Number of subjects: 0
Study: 27720505

Group type: EXPERIMENTAL
Intervention: S-AM/TEL 2.5/40 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: S-AM/TEL 5/40 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: TEL 80 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 183
Study: 24667161

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 1371
Study: 22532005

Group type: EXPERIMENTAL
Intervention: Affective valence during a 10-min treadmill walk
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Affective valence during a 2-min cool down
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Affective valence during a postcool-down seated rest
Number of subjects: 146
Study: 20820459

Group type: EXPERIMENTAL
Intervention: Zoom 2 bleaching agent applied to labial surfaces
Number of subjects: 20

Group type: COMPARATOR
Intervention: No bleaching treatment (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polishing treatment for both groups
Number of subjects: 20
Study: 18005078

Group type: EXPERIMENTAL
Intervention: Supervised exercise (twice weekly for 12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (normal treatment including encouragement to walk regularly)
Number of subjects: 28
Study: 16633088

Group type: EXPERIMENTAL
Intervention: Indapamide (IND) 2.5 mg od
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bendroflumethiazide (BDZ) 2.5 mg od
Number of subjects: 25
Study: 14633756

Group type: EXPERIMENTAL
Intervention: Sufentanil TCI (0.25 ng x ml(‐1) effect‐site concentration at extubation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil TCI with morphine bolus (0.15 mg x kg(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil TCI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil TCI
Number of subjects: 30
Study: 11304887

Group type: EXPERIMENTAL
Intervention: Attention level defined in digit span test
Number of subjects: 40
Study: 8827850

Group type: EXPERIMENTAL
Intervention: 0.02 mg estradiol added to neuroleptic treatment for eight weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neuroleptic treatment alone
Number of subjects: 11
Study: 7967338

Group type: EXPERIMENTAL
Intervention: Ticlopidine, 500 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Aspirin, 320 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: No disaggregants (Control Group 3)
Number of subjects: 80
Study: 3519095

Group type: EXPERIMENTAL
Intervention: 0.1% hexetidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 30222637

Group type: EXPERIMENTAL
Intervention: Subcutaneous microneedle RF treatment (67°C/4‐second duration)
Number of subjects: 50
Study: 27977720

Group type: EXPERIMENTAL
Intervention: RBANS neurocognitive test battery administered on admission and again at discharge (mean time 4.1 weeks, SD 1.86 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Change in PANSS negative symptoms
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison between subjects with schizophrenia and those with other psychotic disorders
Number of subjects: 84
Study: 25509967

Group type: EXPERIMENTAL
Intervention: Rajyoga meditation in addition to routine medical treatment (analgesics and muscle relaxants)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (analgesics and muscle relaxants only)
Number of subjects: 50
Study: 22070769

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 0
Study: 20159703

Group type: EXPERIMENTAL
Intervention: Iodine-125 implantation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no iodine-125 implantation)
Number of subjects: 68
Study: 17706461

Group type: EXPERIMENTAL
Intervention: Multiplayer group (participated in a weekly IDSVG multiplayer class)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Home group (instructed to play IDSVG at home)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multiplayer group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Home group
Number of subjects: 27
Study: 16209977

Group type: EXPERIMENTAL
Intervention: Low left ventricular ejection fraction (< 30%) at 1 year
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Presence of right ventricular dysfunction
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Biventricular dysfunction
Number of subjects: 291
Study: 12427648

Group type: EXPERIMENTAL
Intervention: Non-high-density lipoprotein cholesterol (non-HDL-C)
Number of subjects: 1514

Group type: COMPARATOR
Intervention: HDL-C and LDL-C
Number of subjects: 1514
Study: 10361649

Group type: EXPERIMENTAL
Intervention: Exercise training plus relaxation therapy (relaxation group; n = 76)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Exercise training only (control group; n = 80)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 156
Study: 7741790

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide‐HCl (Cerucal)
Number of subjects: 12
Study: 2048369

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 44
Study: 155507

Group type: EXPERIMENTAL
Intervention: Halcinonide-neomycin-amphotericin (HNA) cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iodochlorhydroxyquin-hydrocortisone (I-HC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydrocortisone (HC)
Number of subjects: 80
Study: 30684710

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10% mannitol plus 10% glycerol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 120
Study: 29136453

Group type: EXPERIMENTAL
Intervention: Locoregional interferon beta (3 million units once per day for 10 consecutive days every 8 weeks for a total of 3 courses, then 1-day injection every 4 weeks for 2.5 years)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Locoregional interferon beta
Number of subjects: 240

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 240
Study: 26334108

Group type: EXPERIMENTAL
Intervention: Intensified maintenance (in-person visits plus telephone calls)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard maintenance (mailed materials)
Number of subjects: 106
Study: 23182126

Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Mirabegron 100mg
Number of subjects: 1978

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Tolterodine 4mg
Number of subjects: 1978
Study: 21929377

Group type: EXPERIMENTAL
Intervention: Single talker auditory training
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Multiple talker auditory training
Number of subjects: 69
Study: 18182756

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 27
Study: 16644310

Group type: EXPERIMENTAL
Intervention: Intensified medical therapy
Number of subjects: 824

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 824
Study: 14663807

Group type: EXPERIMENTAL
Intervention: Positioning splint and plates
Number of subjects: 23
Study: 10964145

Group type: EXPERIMENTAL
Intervention: Lidocaine 10%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 70
Study: 8695135

Group type: EXPERIMENTAL
Intervention: Hotline fluid warmer
Number of subjects: 49

Group type: COMPARATOR
Intervention: Flotem IIe fluid warmer
Number of subjects: 49
Study: 1511646

Group type: EXPERIMENTAL
Intervention: Loperamide (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loperamide oxide (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6511100

Group type: EXPERIMENTAL
Intervention: Ethanol (100ppm toluene + ethanol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cimetidine (100ppm toluene + cimetidine)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Propranolol (100ppm toluene + propranolol)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (100ppm toluene)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (200ppm toluene)
Number of subjects: 4
Study: 29387318

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27031480

Group type: EXPERIMENTAL
Intervention: PWD living alone
Number of subjects: 511

Group type: COMPARATOR
Intervention: PWD not living alone
Number of subjects: 511
Study: 25662857

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 23308361

Group type: EXPERIMENTAL
Intervention: Nutraceuticals containing soy isoflavones (60 mg) and berberine (500 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21127274

Group type: EXPERIMENTAL
Intervention: Thrombin dynamics test (TDT)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 220

Group type: COMPARATOR
Intervention: Aortic valve replacement (AVR) with warfarin treatment
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: F(1+2) levels
Number of subjects: 220
Study: 19149269

Group type: EXPERIMENTAL
Intervention: Sodium ferulate intravenous drip after 24 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic treatment (dehydrating, cytidine diphosphocholine, controlling blood pressure, blood sugar and complicating diseases)
Number of subjects: 60
Study: 16534180

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg b.i.d. via Foradil Aerolizer)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tiotropium (18 microg o.d. via Spiriva HandiHaler)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 38
Study: 12680747

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sertraline (adequate treatment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (adequate treatment)
Number of subjects: 26
Study: 10890988

Group type: COMPARATOR
Intervention: Corticosteroids alone (methylprednisolone or prednisolone at 1 mg/kg, increased by 50% every 5 to 10 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus cyclosporine (5 mg/kg)
Number of subjects: 33
Study: 8822971

Group type: EXPERIMENTAL
Intervention: 5 mg SDZ‐WAG 994
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 mg SDZ‐WAG 994
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 mg SDZ‐WAG 994
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1454457

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3913459

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg 4 times daily) for up to 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral acyclovir and Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo and Oral acyclovir
Number of subjects: 11
Study: 30474929

Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA) patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JIA patients with higher vigorous physical activity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JIA patients
Number of subjects: 60
Study: 28549799

Group type: EXPERIMENTAL
Intervention: Pharmacist-led patient-centered pharmaceutical care (PC)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 514